2CBCB-NBOMe

2CBCB-NBOMe
Legal status
Legal status	In general: legal;
Identifiers
	IUPAC name N-(2-methoxybenzyl)-1-[(7R)-3-bromo-2,5-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methanamine;
ChemSpider	26234935 ;
Chemical and physical data
Formula	C19H22BrNO3
Molar mass	392.286 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COc1ccccc1CNCC3c2c(C3)c(OC)c(Br)cc2OC;
	InChI InChI=1S/C19H22BrNO3/c1-22-16-7-5-4-6-12(16)10-21-11-13-8-14-18(13)17(23-2)9-15(20)19(14)24-3/h4-7,9,13,21H,8,10-11H2,1-3H3/t13-/m0/s1 ; Key:CLSBQRBXTFTLEX-ZDUSSCGKSA-N ;
	(verify)

2CBCB-NBOMe (NBOMe-TCB-2) is a compound indirectly derived from the phenethylamine series of hallucinogens, which was discovered in 2007 at Purdue University as part of the ongoing research program of the team led by David Nichols focusing on the mapping of the specific amino acid residues responsible for ligand binding to the 5HT_2A receptor. 2CBCB-NBOMe acts as a potent and selective agonist for the 5-HT_2A and 5-HT_2C receptors, with a Ki of 0.27nM at the human 5-HT_2A receptor, a similar potency to other agonists such as TCB-2, NBOMe-2C-I and bromodragonfly^[1]

References

^ Michael Robert Braden PhD. Towards a biophysical understanding of hallucinogen action. Purdue University 2007.

This hallucinogen-related article is a stub. You can help Wikipedia by expanding it.

[1] Michael Robert Braden PhD. Towards a biophysical understanding of hallucinogen action. Purdue University 2007.

[1]

See also

References